Hyperuricemia is arbitarily defined as serum or plasma urate concentration >7 mg/dl in males and >6 mg/dl in females (5). At this concentration of urate, the limit of solubility of MSU in plasma at 37°C is exceeded (6).
Gouty Arthritis
V
Epidemiology
Gout is the single most common cause of inflammatory arthritis in males above the age of40 years (3) . Though hyperuricemia is the single most important risk factor for the causation of gout, the epidemiology of gout and hyperuricemia are different (4) .
Hyperuricemia is arbitarily defined as serum or plasma urate concentration >7 mg/dl in males and >6 mg/dl in females (5) . At this concentration of urate, the limit of solubility of MSU in plasma at 37°C is exceeded (6) .
The risk of gouty arthritis and renal stones increases in proportion to serum urate concentrations. The five year cumulative incidence rates of gouty arthritis for serum urate level of 8 mg/dl has been reported to be 2% as compared to 19 .8% for urate levels 9-1 0 mg/dl and 30% for> 10 mg/dl (7). Serum urate level increases sharply at pubelty in males and at menopause in females (5) .
Therefore, gout is very uncommon in premenopausal females and males below 30 years of age (1,5,6). The precise incidence and prevalence rate of gout is difficult to determine because of remitting and relapsing nature of the disease, propensity to misdiagnosis (over diagnosis by patients), changing life styles, eating habits and longevity of life in different population worldwide (8).
Male to female ratio has been reported to vary from 2-7: 1 in different series (3, 9) . Data on the epidemiological profile oflndian patients is scantily repolted inlite~ature.
In a recent population based study from South Korea, the prevalence of hyperuricemia has been reported to be 25.8% in males and 15% in females whereas 11.5% of males and 3% offemales with hyperuricemia had gout (10) . Western figures for the prevalence of hyperuricemia and gout varies 2-13% and 1.3-3.7% respectively, in the general population (11) . Various risk factors which predisposes to gout are obesity, alcohol intake, hypeltension, renal insufficiency, diuretics use, family history of gout and environmental or occupational exposure to lead.
Clinical Presentations of Gout
The natural history of gout is comprised of 4 phases Tophaceous gout is often associated with early age of onset, frequent acute attacks, high serum uric acid levels, polyarticular involvement at onset and renal dysfunction (I). However, with the use of uric acid lowering drugs and the ability to control hyperuricemia, incidence of tophi has decreased from 53% to 17% (IS). Another series has reported the incidence of tophaceous gout to as low as 3% (3). However, the prevalence of tophaceous gout remain high in untreated patients.
Potential for Misdiagnosis of Gout
Idiopathic hyperuricemia is much more common than the clinical gout, and a flare ofOA ofTst MTP in a patient with hyperuricemia can be misdiagnosed as gout. Acute hot joint in a patient receiving chemotherapy for maligancy or a transplant recipient on cyclosporine may be due to secondary gout (16) but may be labelled as septic al1hritis. Similarly, an acute hot joint in a patient with chronic gout may be misdiagnosed to be due to acute flare whereas it may be due to septic aI1hritis due 
Classification and Etiopathogenesis
Gout is classified into 2 main groups; over production or under secretion of uric acid (Table I) Asymptomatic hyperuricemia should not be treated as most of the patients will never develop gout (12), However, in a setting of malignancy, xanthine oxidase inhibitors should be started along with good hydration (urine output> 100 ml/hour) prior to start of chemotherapy so as to prevent acute uric acid nephropathy. Earlier, this entity was associated with mortality up to 59% however, nowadays with proper hydration and antihyperuricemic therapy mortality is almost nil. Majority of the patients presenting with acute monoarticular gouty arthritis should be stratified and treated as per the protocol mentioned above (Table-2 
